167 related articles for article (PubMed ID: 9382447)
1. Anthracycline cardiotoxicity and its prevention.
Mott MG
Ann N Y Acad Sci; 1997 Sep; 824():221-8. PubMed ID: 9382447
[No Abstract] [Full Text] [Related]
2. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
3. New drug counters doxorubicin cardiotoxicity; not for use at start of chemotherapy.
Am J Health Syst Pharm; 1995 Oct; 52(19):2076. PubMed ID: 8535936
[No Abstract] [Full Text] [Related]
4. Anthracyclines: cardiotoxicity and its prevention.
Hale JP; Lewis IJ
Arch Dis Child; 1994 Nov; 71(5):457-62. PubMed ID: 7826122
[No Abstract] [Full Text] [Related]
5. Anthracycline cardiotoxicity prevention by dexrazoxane: breakthrough of a barrier--sharpens antitumor profile and therapeutic index.
Hellmann K
J Clin Oncol; 1996 Feb; 14(2):332-3. PubMed ID: 8636740
[No Abstract] [Full Text] [Related]
6. Clinical status and optimal use of the cardioprotectant, dexrazoxane.
Blum RH
Oncology (Williston Park); 1997 Nov; 11(11):1669-77; discussion 1677-8, 1681. PubMed ID: 9394365
[No Abstract] [Full Text] [Related]
7. [The role of cardioxane (ICRF-187) in the prevention of cardiotoxicity of anthracyclines in the combined drug therapy of extensive ovarian cancer].
Protasov DA; Zel'dovich DR; Kuz'mina LP; Manikhas GM
Vopr Onkol; 1998; 44(6):718-21. PubMed ID: 10087973
[TBL] [Abstract][Full Text] [Related]
8. Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care.
Hellmann K
Support Care Cancer; 1996 Jul; 4(4):305-7. PubMed ID: 8829310
[TBL] [Abstract][Full Text] [Related]
9. [Cardioxan--a drug of prevention of anthracycline-related cardiotoxicity in pediatric oncology].
Kolygin BA
Vopr Onkol; 2002; 48(1):110-2. PubMed ID: 12101558
[No Abstract] [Full Text] [Related]
10. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
Wiseman LR; Spencer CM
Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
[TBL] [Abstract][Full Text] [Related]
11. Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.
Choi HS; Park ES; Kang HJ; Shin HY; Noh CI; Yun YS; Ahn HS; Choi JY
J Korean Med Sci; 2010 Sep; 25(9):1336-42. PubMed ID: 20808678
[TBL] [Abstract][Full Text] [Related]
12. Rationale and strategy for prevention of anthracycline cardiotoxicity with the bisdioxopiperazine, ICRF-187.
Green MD
Pathol Biol (Paris); 1987 Jan; 35(1):49-53. PubMed ID: 3550612
[TBL] [Abstract][Full Text] [Related]
13. Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.
Elbl L; Hrstkova H; Tomaskova I; Blazek B; Michalek J
Eur J Pediatr; 2005 Nov; 164(11):678-84. PubMed ID: 16044276
[TBL] [Abstract][Full Text] [Related]
14. Indium-111-antimyosin scintigraphy in the early detection of heart damage after anthracycline therapy in children.
Kremer LC; Tiel-van Buul MM; Ubbink MC; Offringa M; Ottenkamp J; Olmos RV; Voûte PA
J Clin Oncol; 1999 Apr; 17(4):1208. PubMed ID: 10561180
[TBL] [Abstract][Full Text] [Related]
15. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children.
Lipshultz SE
J Clin Oncol; 1996 Feb; 14(2):328-31. PubMed ID: 8636739
[No Abstract] [Full Text] [Related]
16. Doxorubicin-induced myocardial injury.
Fujisaki G; Inokuchi C; Murashige N
N Engl J Med; 2004 Oct; 351(18):1908-9; author reply 1908-9. PubMed ID: 15509827
[No Abstract] [Full Text] [Related]
17. Cardiotoxicity of doxorubicin and other anthracycline derivatives.
Jain D
J Nucl Cardiol; 2000; 7(1):53-62. PubMed ID: 10698235
[No Abstract] [Full Text] [Related]
18. Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease.
Bu'Lock FA; Gabriel HM; Oakhill A; Mott MG; Martin RP
Br Heart J; 1993 Aug; 70(2):185-8. PubMed ID: 8038032
[TBL] [Abstract][Full Text] [Related]
19. [Cardioxan as a cardioprotector in antineoplastic chemotherapy].
Lichinitser MP; Vyshinskaia GV; Min'kov ED; Nakhalova TA; Odzharova AA; Garin AM
Klin Med (Mosk); 1996; 74(5):65-7. PubMed ID: 8999195
[No Abstract] [Full Text] [Related]
20. [Dexrazoxane and cardiotoxicity in repeatedly treated patients].
Trnĕný M
Vnitr Lek; 2004 Jun; 50(6):417-8. PubMed ID: 15346632
[No Abstract] [Full Text] [Related]
[Next] [New Search]